A Phase 2 interventional study of SLx-4090 and Placebo in Type 2 Diabetes, sponsored by Response Pharmaceuticals. Completed at 12 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by Response Pharmaceuticals · Phase 2, Interventional, and Treatment
The purpose of this study is to determine whether SLx-4090 in combination with metformin therapy will reduce HbA1c in patients with Type 2 Diabetes more effectively than metformin therapy alone.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 82 is close to the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Response Pharmaceuticals is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
SLx-4090 in combination with Metformin
Drug: SLx-4090 · Drug: Metformin
Placebo
Other: Placebo · Drug: Metformin
SLx-4090
matching tablets
Reduction in HbA1c
Time frame: 12 weeks
Adverse Events
Time frame: 12 weeks
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Response Pharmaceuticals